BIIB 059

Next Previous
Drug Profile

BIIB 059

Alternative Names: BIIB-059

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Monoclonal antibodies
  • Mechanism of Action C-type lectin modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous lupus erythematosus; Systemic lupus erythematosus

Most Recent Events

  • 26 Sep 2017 Biogen initiates enrolment in a phase I trial in Healthy volunteers in USA (SC) (NCT03224793)
  • 24 Jul 2017 Biogen plans a phase I trial in Healthy volunteers (SC) (NCT03224793)
  • 14 Jun 2017 Pharmacodynamics and adverse events data from a phase I trial in Systemic lupus erythematosus 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top